Biotech Stocks Hit New 52-Week Highs: Atai Life Sciences, Cidara Therapeutics, aTyr Pharma.

Biotech stocks Atai Life Sciences (ATAI), Cidara Therapeutics (CDTX), aTyr Pharma (ATYR), and others hit new 52-week highs on Friday. ATAI awaits key data readout from Recognify Life Sciences, while CDTX announced positive phase IIb trial results for CD388 and bolstered its cash position. aTyr Pharma gears up for a phase III trial of Efzofitimod in pulmonary sarcoidosis. Shares of these companies have seen significant gains since they were last profiled on our site.

Biotech stocks Atai Life Sciences (ATAI), Cidara Therapeutics (CDTX), aTyr Pharma (ATYR), and others hit new 52-week highs on Friday, reflecting positive developments in their clinical trial programs. These gains come as investors anticipate key data readouts and milestones that could significantly impact stock prices.

Atai Life Sciences (ATAI) touched a new 52-week high of $3.35, driven by expectations for a key data readout from Recognify Life Sciences, a company in which Atai holds a majority stake. Recognify is developing RL-007, an investigational treatment for Cognitive Impairment Associated with Schizophrenia (CIAS). The data readout is expected in mid-2025. ATAI’s stock has surged approximately 42% since it was last profiled on June 4, 2025 [1].

Cidara Therapeutics (CDTX) also reached a new 52-week high of $61.54 on Friday. The company announced positive results from its phase IIb trial of CD388, a non-vaccine preventative of seasonal influenza. CDTX has sought an end-of-phase II meeting with the FDA to review the trial results and further discuss the phase III trial design and start time. The company raised $402.5 million from a public offering and was added to the Russell 2000 and Russell 3000 Indexes on June 30, 2025. CDTX was last profiled on June 23, 2025, when it was trading at $40.63 [1].

aTyr Pharma (ATYR) touched a 52-week high of $6.44 on Friday, as the company gears up for an important upcoming milestone. Topline data from a phase III trial of lead investigational drug Efzofitimod in patients with pulmonary sarcoidosis, dubbed EFZO-FIT, are due this quarter (Q3, 2025). ATYR was last profiled on July 14, 2025, when it was trading at $5.30 [1].

Maze Therapeutics (MAZE), which debuted on the Nasdaq early this year, has a clinical trial catalyst to watch related to MZE782, its investigational drug for chronic kidney disease and phenylketonuria. Initial data from a phase I trial of MZE782, including proof-of-mechanism biomarker results, are anticipated this quarter (Q3 2025). MAZE’s stock touched an all-time high of $18.50 on July 18, 2025, reflecting a gain of 65% in less than 2 months [1].

Cogent Biosciences (COGT) touched a 52-week high of $12.95 on Friday. The company announced positive top-line results from Part 2 of its phase II trial of Bezuclastinib in patients with Non-Advanced Systemic Mastocytosis, dubbed SUMMIT. Bezuclastinib is also under a phase II trial in people with Advanced Systemic Mastocytosis, dubbed APEX, with topline data expected in the second half of 2025. COGT was last featured on July 2, 2025, when it was at $7.25 [1].

Metsera Inc. (MTSR) touched an all-time high of $47.40 on Friday. A phase IIb trial designed to assess weight loss of different weekly doses of MET-097i over 28 weeks in participants with obesity or overweight without type 2 diabetes, dubbed VESPER-1, is underway, with preliminary results expected in mid-2025. MTSR was last alerted on June 10, 2025, when it was trading at $32.35 [1].

References:
[1] https://www.nasdaq.com/articles/atai-impresses-cdtx-navigates-confidence-mtsr-builds-momentum-cogt-keeps-scaling-summit
[2] https://finimize.com/content/atai-asset-snapshot